Sabril and Optic atrophy - a phase IV clinical study of FDA data

Summary:

Optic atrophy is reported as a side effect among people who take Sabril (vigabatrin), especially for people who are female, 0-1 old, have been taking the drug for < 1 month also take Vimpat, and have Infantile spasms.

The phase IV clinical study analyzes which people have Optic atrophy when taking Sabril. It is created by eHealthMe based on reports of 12,433 people who have side effects when taking Sabril from the FDA, and is updated regularly.

What is Sabril?

Sabril has active ingredients of vigabatrin. eHealthMe is studying from 12,445 Sabril users. Check the latest studies of Sabril.

What is Optic atrophy?

Optic atrophy (the loss of a proportion of optic disc nerve fibres) is found to be associated with 249 drugs and 453 conditions by eHealthMe. Check the latest studies of Optic atrophy.

On Jul, 17, 2026

12,433 people reported to have side effects when taking Sabril.
Among them, 57 people (0.46%) have Optic atrophy.

Among these 57 people:

How long have people been on Sabril when they have Optic atrophy? *

What is the gender of people who have Optic atrophy when taking Sabril? *

female: 55.56 %
male: 44.44 %

What is the age of people who have Optic atrophy when taking Sabril? *

What are other drugs people take besides Sabril? *

What are other side effects people have besides Optic atrophy? *

Visual Impairment: 9 people, 15.79%
Visual Field Defect: 8 people, 14.04%
The Flu (the flu is caused by an influenza virus): 7 people, 12.28%
Retinogram Abnormal: 5 people, 8.77%
Blindness Unilateral: 3 people, 5.26%
Eye Movements - Uncontrollable: 3 people, 5.26%
Blindness: 3 people, 5.26%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 2 people, 3.51%
Fundoscopy Abnormal: 2 people, 3.51%
Retinal Disorder (disease of retina): 2 people, 3.51%

What are the existing conditions these people have? *

Infantile Spasms: 20 people, 35.09%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 4 people, 7.02%
Nausea (feeling of having an urge to vomit): 2 people, 3.51%
Complex Partial Seizures (epileptic seizure): 2 people, 3.51%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 2 people, 3.51%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 2 people, 3.51%
Temporal Lobe Epilepsy (a term that refers to a condition where seizures are generated in the portion of the brain called the temporal lobe): 2 people, 3.51%
Lacrimation Increased: 1 person, 1.75%
Nausea And Vomiting: 1 person, 1.75%
Hypersensitivity: 1 person, 1.75%

* Approximation only. Some reports may have incomplete information.

Do you take Sabril and have Optic atrophy?

- Check whether Optic atrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sabril:

Sabril (12,445 reports)

Optic atrophy treatments and more:

Optic atrophy (2,242 reports)

Browse all side effects of Sabril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Optic atrophy:

Optic atrophy (249 drugs)

Browse all the conditions that are associated with Optic atrophy:

Optic atrophy (453 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vigabatrin (the active ingredients of Sabril) and Sabril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.